Technology Procedure Specification
Procedure guideline of 99Tcm-pyrophosphate scintigraphy in the diagnosis of transthyretin-related cardiac amyloidosis
Cardiology Group of Chinese Society of Nuclear Medicine, National Center for Quality Control of Nuclear Medicine
Published 2022-03-25
Cite as Chin J Nucl Med Mol Imaging, 2022, 42(3): 165-171. DOI: 10.3760/cma.j.cn321828-20210909-00320
Abstract
Transthyretin-related cardiac amyloidosis (ATTR-CA) is caused by the deposition of amyloid protein in the intercellular space of cardiomyocytes. Due to the lack of specificity of clinical manifestations and the barriers of early identification, diagnosis and treatment seriously affect the survival rate and life quality of patients. With the developments of noninvasive diagnostic technologies and effective drugs in recent years, timely diagnosis and precise treatment significantly improve the prognosis of patients. 99Tcm-pyrophosphate (PYP) can visualize ATTR-CA noninvasively, and the standardized acquisition and image analysis are very critical for the clinical application. This article highlights the recommendations on 99Tcm-PYP SPECT (/CT) imaging of ATTR-CA based on the local and global imaging experience and research progress, in order to in line with Chinese clinical conditions of diagnosis and treatment for more convenient promotion.
Key words:
Amyloidosis; Myocardium; Prealbumin; Radionuclide imaging; Tomography, emission-computed, single-photon; Technetium Tc 99m pyrophosphate
Contributor Information
Cardiology Group of Chinese Society of Nuclear Medicine
National Center for Quality Control of Nuclear Medicine